Chen W, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016;35:73.
Article
PubMed
PubMed Central
Google Scholar
Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894–906.
Article
PubMed
Google Scholar
Zhang ZL, Li YH, Xiong YH, Hou GL, Yao K, Dong P, et al. Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma. Chin J Cancer. 2010;29:995–9.
Article
CAS
PubMed
Google Scholar
Wagstaff J, Jones R, Hawkins R, Porfiri E, Pickering L, Bahl A, et al. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol. 2016;27:159–65.
Article
CAS
PubMed
Google Scholar
Woo SM, Min KJ, Chae IG, Chun KS, Kwon TK. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways. Mol Carcinog. 2015;54:216–28.
Article
CAS
PubMed
Google Scholar
Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110:2821–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sircar K, Rao P, Jonasch E, Monzon FA, Tamboli P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer. 2013;32:303–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, et al. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer. 2011;117:4201–11.
Article
CAS
PubMed
Google Scholar
Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27:4709–17.
Article
PubMed
Google Scholar
Fu Q, Chang Y, Zhou L, An H, Zhu Y, Xu L, et al. Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients. Oncotarget. 2016;7:8413–21.
PubMed
Google Scholar
Li X, Ma X, Chen L, Gu L, Zhang Y, Zhang F, et al. Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2015;5:13157.
Article
CAS
PubMed
PubMed Central
Google Scholar
Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113:450–60.
Article
PubMed
PubMed Central
Google Scholar
Lucarelli G, Galleggiante V, Rutigliano M, Sanguedolce F, Cagiano S, Bufo P, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6:13371–86.
Article
PubMed
PubMed Central
Google Scholar
de Martino M, Taus C, Lucca I, Hofbauer SL, Haitel A, Shariat SF, et al. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. Mol Carcinog. 2016;55:1458–66.
Article
PubMed
Google Scholar
Bigot P, Lughezzani G, Karakiewicz P, Perrotte P, Rioux-Leclercq N, Catros-Quemener V, et al. The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality. J Urol. 2010;183:486–91.
Article
PubMed
Google Scholar
Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, et al. Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer. 2009;101:1175–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, et al. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. Br J Cancer. 2015;113:1581–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermüller N, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer. 2009;45:478–89.
Article
CAS
PubMed
Google Scholar
Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, et al. Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer. 2008;123:1080–8.
Article
CAS
PubMed
Google Scholar
Liu Y, Han X, Yu Y, Ding Y, Ni C, Liu W, et al. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression. Sci Rep. 2016;6:26689.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chaly Y, Hostager B, Smith S, Hirsch R. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunol Res. 2014;59:266–72.
Article
CAS
PubMed
Google Scholar
Wilson DC, Marinov AD, Blair HC, Bushnell DS, Thompson SD, Chaly Y, et al. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arth rheum. 2010;62:2510–6.
Article
CAS
Google Scholar
Wei K, Serpooshan V, Hurtado C, Diez-Cuñado M, Zhao M, Maruyama S, et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature. 2015;525:479–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hayakawa S, Ohashi K, Shibata R, Kataoka Y, Miyabe M, Enomoto T, et al. Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal nephrectomy model. J Am Soc Nephrol. 2015;26:636–46.
Article
CAS
PubMed
Google Scholar
Kudo-Saito C, Fuwa T, Murakami K, Kawakami Y. Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction. Cancer Res. 2013;73:6185–93.
Article
CAS
PubMed
Google Scholar
Su S, Parris AB, Grossman G, Mohler JL, Wang Z, Wilson EM. Up-regulation of follistatin-like 1 by the androgen receptor and melanoma antigen-A11 in prostate cancer. Prostate. 2017;77:505–16.
Article
CAS
PubMed
Google Scholar
Torres S, Bartolome RA, Mendes M, Barderas R, Fernandez-Aceñero MJ, Peláez-García A, et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res. 2013;19:6006–19.
Article
CAS
PubMed
Google Scholar
Chen SX, Xu XE, Wang XQ, Cui SJ, Xu LL, Jiang YH, et al. Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation. J Proteomics. 2014;110:155–71.
Article
CAS
PubMed
Google Scholar
Chan QK, Ngan HY, Ip PP, Liu VW, Xue WC, Cheung AN. Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis. Carcinogenesis. 2009;30:114–21.
Article
CAS
PubMed
Google Scholar
Tan X, He S, Han Y, Yu Y, Xiao J, Xu D, et al. Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients. Cancer Cell Int. 2013;13:20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun W, Tan X, Shi Y, Xu G, Mao R, Gu X, et al. USP11 negatively regulates TNFalpha-induced NF-kappaB activation by targeting on IkappaBalpha. Cell Signal. 2010;22:386–94.
Article
CAS
PubMed
PubMed Central
Google Scholar
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.
Article
CAS
PubMed
Google Scholar
Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, et al. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression. Br J Cancer. 2013;109:3105–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA. Divergent gene regulation and growth effects by NF-κB in epithelial and mesenchymal cells of human skin. Oncogene. 2003;22:1955–64.
Article
CAS
PubMed
Google Scholar
Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J Biol Chem. 2006;281:15215–26.
Article
CAS
PubMed
Google Scholar
Lin L, Wu Q, Chang W, Chang WJ, Hou JG, Zhang HW, Tan XJ, et al. Identification of metastasis-associated alternatively spliced variants of CD99 in clear cell renal cell carcinoma tissues. Acad J Second Mili Med Univ. 2009;30:355–9 [in Chinese].
Article
CAS
Google Scholar
Ghuwalewala S, Ghatak D, Das P, Dey S, Sarkar S, Alam N, et al. CD44highCD24low molecular signature determines the cancer stem cell and EMT phenotype in oral squamous cell carcinoma. Stem cell Res. 2016;16:405–17.
Article
CAS
PubMed
Google Scholar
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98:756–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
D’Amico L, Patane S, Grange C, Bussolati B, Isella C, Fontani L, et al. Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. Br J Cancer. 2013;108:2525–36.
Article
PubMed
PubMed Central
Google Scholar
Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1α protein by recruiting histone deacetylase 1. EMBO J. 2006;25:1231–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Juengel E, Nowaz S, Makarevi J, Natsheh I, Werner I, Nelson K, et al. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Mol Cancer. 2014;13:152.
Article
PubMed
PubMed Central
Google Scholar
Bharti R, Dey G, Mandal M. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement. Cancer Lett. 2016;375:51–61.
Article
CAS
PubMed
Google Scholar
Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, et al. Targeting the nuclear factor-κB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res. 2007;67:11668–76.
Article
CAS
PubMed
Google Scholar
Schodel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69:646–57.
Article
PubMed
Google Scholar
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.
Article
Google Scholar
Micucci C, Matacchione G, Valli D, Orciari S, Catalano A. HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer. 2015;113:1178–85.
Article
CAS
PubMed
PubMed Central
Google Scholar